Story · Europe
BioGaia AB (publ) Q2 2026 Earnings Call Transcript
BioGaia AB reported its Q2 2026 financial results, with net sales reaching SEK 441 million, representing 12% growth excluding currency effects. The company achieved an operating profit of SEK 132 million, up 22% year-over-year, with an EBIT margin of 30% and an adjusted EBIT margin of 33%. Regional performance varied: Europe, Middle East, and Africa saw a 21% sales increase; the Americas grew 16%; while Asia Pacific declined 6% due to order variability. Year-to-date net sales reached SEK 813 million with 13% growth excluding currency effects. CEO Theresa Agnew reiterated the company's strategic pillars, focusing on growing the core health areas of Gut Health, colic, oral health, and immune health.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection